samedan logo
 
 
spacer
home > white papers > Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery - Presspart Manufacturing Ltd
WHITE PAPERS
logo_Presspart_5.jpg

Presspart Manufacturing Ltd

phone +44 1254 584131
email chad.mayoh@presspart.com
web http://www.presspart.com
email Whitebirk Industrial Estate, Blackburn, BB1 5RF

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

The smart device improving access to hearing healthcare

The smart device improving access to hearing healthcare A team of doctors and medical device engineers have developed the world’s first all-in-one hearing health assessment device, to help make ear healthcare more accessible to the public. The device, a portable smartphone-enabled otoscope, has the potential to shave months off waiting times for patients and ease pressure on healthcare.
More info >>


White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>


Industry Events

A Magic Triangle: Practical insights into lactose-based DPI formulations

30 June 2021, Online webinar

Three leading companies with complementary areas of expertise have joined forces to conduct a unique multidisciplinary study into lactose-based DPI formulations including magnesium stearate. Their findings will give generic players a head start in the development process so that they can tap into this rapidly growing market. Lactose specialist DFE Pharma, powder processing technology manufacturer Hosokawa Micron and machine-building expert Harro Hoefliger will be presenting the key insights from their research to interested parties during a joint webinar on the 30th of June.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement